US12649794B2 - Anti-galectin-9 antibody and uses thereof - Google Patents

Anti-galectin-9 antibody and uses thereof

Info

Publication number
US12649794B2
US12649794B2 US17/789,961 US202117789961A US12649794B2 US 12649794 B2 US12649794 B2 US 12649794B2 US 202117789961 A US202117789961 A US 202117789961A US 12649794 B2 US12649794 B2 US 12649794B2
Authority
US
United States
Prior art keywords
seq
sequence
antibody
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/789,961
Other languages
English (en)
Other versions
US20230054718A1 (en
Inventor
Germain MARGALL DUCOS
Rachel PACHERIE
Nicola Arturo Aldo Beltraminelli
Francisco Adrian
Liang Schweizer
Muriel David
Yun-Yueh LU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HiFiBiO Inc
Original Assignee
HiFiBiO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HiFiBiO Inc filed Critical HiFiBiO Inc
Priority to US17/789,961 priority Critical patent/US12649794B2/en
Assigned to HIFIBIO (HK) LIMITED reassignment HIFIBIO (HK) LIMITED ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: BELTRAMINELLI, Nicola Arturo Aldo, DAVID, Muriel, MARGALL DUCOS, Germain, PACHERIE, Rachel, LU, Yun-Yueh, SCHWEIZER, Liang, ADRIAN, FRANCISCO
Publication of US20230054718A1 publication Critical patent/US20230054718A1/en
Assigned to HIFIBIO, INC. reassignment HIFIBIO, INC. ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: HIFIBIO (HK) LIMITED
Application granted granted Critical
Publication of US12649794B2 publication Critical patent/US12649794B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
US17/789,961 2020-01-07 2021-01-06 Anti-galectin-9 antibody and uses thereof Active 2043-10-10 US12649794B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/789,961 US12649794B2 (en) 2020-01-07 2021-01-06 Anti-galectin-9 antibody and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957910P 2020-01-07 2020-01-07
PCT/CN2021/070473 WO2021139682A1 (en) 2020-01-07 2021-01-06 Anti-galectin-9 antibody and uses thereof
US17/789,961 US12649794B2 (en) 2020-01-07 2021-01-06 Anti-galectin-9 antibody and uses thereof

Publications (2)

Publication Number Publication Date
US20230054718A1 US20230054718A1 (en) 2023-02-23
US12649794B2 true US12649794B2 (en) 2026-06-09

Family

ID=74194447

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/789,961 Active 2043-10-10 US12649794B2 (en) 2020-01-07 2021-01-06 Anti-galectin-9 antibody and uses thereof

Country Status (11)

Country Link
US (1) US12649794B2 (enExample)
EP (1) EP4087873A1 (enExample)
JP (1) JP7719799B2 (enExample)
KR (1) KR20220123105A (enExample)
CN (2) CN120647763A (enExample)
AU (1) AU2021205143A1 (enExample)
BR (1) BR112022013494A2 (enExample)
CA (1) CA3163988A1 (enExample)
IL (1) IL294466A (enExample)
MX (1) MX2022008421A (enExample)
WO (1) WO2021139682A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3021970B1 (fr) † 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
AU2021205143A1 (en) 2020-01-07 2022-07-28 Hifibio, Inc. Anti-Galectin-9 antibody and uses thereof
KR20250029919A (ko) * 2022-06-29 2025-03-05 퓨어테크 엘와이티, 아이엔씨. 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료
EP4554682A1 (en) 2022-07-15 2025-05-21 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN120585880B (zh) * 2025-08-07 2025-12-09 四川大学华西医院 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007075598A2 (en) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036653A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008132601A1 (en) 2007-04-30 2008-11-06 Immutep Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009044273A2 (en) 2007-10-05 2009-04-09 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2010019570A2 (en) 2008-08-11 2010-02-18 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RU2397249C2 (ru) 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ
WO2011028683A1 (en) 2009-09-03 2011-03-10 Schering Corporation Anti-gitr antibodies
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
WO2011070024A1 (en) 2009-12-10 2011-06-16 F. Hoffmann-La Roche Ag Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011140249A2 (en) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2012032433A1 (en) 2010-09-09 2012-03-15 Pfizer Inc. 4-1bb binding molecules
WO2012142237A1 (en) 2011-04-15 2012-10-18 Newlink Geneticks Corporation Fused imidazole derivatives useful as ido inhibitors
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2013119716A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
WO2013132044A1 (en) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and uses thereof
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2015031667A2 (en) 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
US20170283499A1 (en) 2014-06-06 2017-10-05 Universite Sciences Technologies Lille Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory t lymphocytes
US20190127472A1 (en) 2017-10-27 2019-05-02 New York University Anti-galectin-9 antibodies and uses thereof
WO2019197675A1 (en) 2018-04-13 2019-10-17 Argenx Bvba Galectin-10 antibodies
WO2020018364A1 (en) 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CA3134942A1 (en) 2019-03-25 2020-10-01 New York University Anti-galectin-9 antibodies and uses thereof
WO2020223702A1 (en) 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
KR20130103587A (ko) * 2010-12-09 2013-09-23 가르파마 컴퍼니 리미티드 갈렉틴 9를 분비하는 세포, 그 제조 방법 및 그 용도

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
RU2397249C2 (ru) 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007075598A2 (en) 2005-12-20 2007-07-05 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036653A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008132601A1 (en) 2007-04-30 2008-11-06 Immutep Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009044273A2 (en) 2007-10-05 2009-04-09 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2010019570A2 (en) 2008-08-11 2010-02-18 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2011028683A1 (en) 2009-09-03 2011-03-10 Schering Corporation Anti-gitr antibodies
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
WO2011070024A1 (en) 2009-12-10 2011-06-16 F. Hoffmann-La Roche Ag Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011140249A2 (en) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2012032433A1 (en) 2010-09-09 2012-03-15 Pfizer Inc. 4-1bb binding molecules
WO2012142237A1 (en) 2011-04-15 2012-10-18 Newlink Geneticks Corporation Fused imidazole derivatives useful as ido inhibitors
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2013119716A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
WO2013132044A1 (en) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and uses thereof
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2015031667A2 (en) 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
US20170283499A1 (en) 2014-06-06 2017-10-05 Universite Sciences Technologies Lille Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory t lymphocytes
US20190127472A1 (en) 2017-10-27 2019-05-02 New York University Anti-galectin-9 antibodies and uses thereof
WO2019197675A1 (en) 2018-04-13 2019-10-17 Argenx Bvba Galectin-10 antibodies
WO2020018364A1 (en) 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CA3134942A1 (en) 2019-03-25 2020-10-01 New York University Anti-galectin-9 antibodies and uses thereof
WO2020223702A1 (en) 2019-05-01 2020-11-05 New York University Anti-galectin-9 antibodies and uses thereof
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
WO2024015993A1 (en) 2022-07-15 2024-01-18 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof

Non-Patent Citations (62)

* Cited by examiner, † Cited by third party
Title
Angal et al. "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (lgG4) antibody" Jan. 1993, Mol. Immunol. 30(1):105-108.
Clackson et al. "Making antibody fragments using phage display libraries" Aug. 15, 1991, Nature 352(6336):624-628.
Gennaro, "Remington: The Science and Practice of Pharmacy" 20th ed., 2003 (Cover and TOC).
Green et al. "Molecular Cloning: A Laboratory Manual" 4th Ed, 2012, Cold Spring Harbor Laboratory Press, Woodbury, NY (2,028 pages).
Haeckel et al. "XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic2" Jun. 13, 2016, PLoS One 11(6):e0157193.
Harlow and Lane, Antibodies, A Laboratory Manual, 1st Ed., 1988, Cold Springs Harbor Press—726 Pages—Background only—Abstract only (ISBN: 0879693142).
Hoogenboom et al. "By-passing Immunization: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro" 1992, J. Mol. Biol. 227(2):381-388.
International Search Report and Written Opinion for PCT/CN2021/070473 mailed Jun. 14, 2021.
International Search Report and Written Opinion for PCT/CN2021/103889 mailed Mar. 31, 2022.
International Search Report and Written Opinion for PCT/US2023/070259 dated Dec. 13, 2023 (21 pages).
Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., 2000, Pharmaceutical Press (12 pages).
Lhuillier C, et al. Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9. PLoS One. Sep. 11, 2018;13(9):e0202512. doi: 10.1371/journal.pone.0202512. PMID: 30204750; PMCID: PMC6133441. (Year: 2018). *
Marks et al. "By-passing immunization. Human antibodies from V-gene libraries displayed on phage" Dec. 1991, J. Mol. Biol. 222(3):581-597.
Morel et al. "Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations" Jan. 1988, Molec. Immunol. 25(1):7-15.
Morimoto et al. "Single-step purification of F(ab′)2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW" Mar. 1992, J. Biochem. Biophys. Methods 24(1-2):107-117.
Morrison et al. "Transfectomas provide novel chimeric antibodies" Sep. 20, 1985, Science 229(4719):1202-1207.
Nasonov, "Immune Checkpoint Inhibition and Autoimmunity: Rhemuatological Problems", Rheumatology Science and Practice, 2018, 56(1):5-9 (in Russian, with English Abstract).
Oi et al. "Chimeric Antibodies" 1986, BioTechniques 4:214-221.
Pluckthun, "Antibodies from Escherichia coli."1994, The Pharmacology of Monoclonal Antibodies 113:269-315, Rosenberg and Moore eds., Springer-Verlag, NY—Background only—Abstract only.
Raybould et al. "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" 2019 PNAS USA 116(10):4025-4030.
Safdari et al. "Antibody humanization methods—a review and update" 2013, Biotech. And Genetic Engineering Reviews 29(2):175-186.
Sitaraman et al. "High-throughput protein expression using cell-free system" 2009, Methods Mol. Biol. 498:229-244.
Strickley et al "A review of formulatons of commercially available antibodies" Jul. 2021, J. Pharm. Sci. 110(7):2590-2608.e56.
Tyner et al. "Functional Genomic Landscape of Acute Myeloid Leukaemia" Oct. 2018, Nature 562(7728):526-531.
U.S. Appl. No. 18/995,102, filed Jul. 14, 2023, Olsen, David. *
Valldorf et al. "Antiobody Display Technologies: selecting the cream of the crop" 2022, Biol. Chem. 403(506):4550477.
Warszawski et al. "Optimizing Antibody Affinity and Stability by the Automated Design of the Variable Light-Heavy Chain Interfaces" Aug. 23, 2019, PloS Comput. Biol. 16(10):e100207 (http://doi.org/10.1371/journal.pcbi.1007207).
Weber et al. "From rabbit antibody repertoires to rabbit monoclonal antibodies" Mar. 24, 2017, Exp. Mol. Med. 49: e305.
Wu et al. "Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells" 2014, Immunity 41(2):270-282.
Yang et al. "Elevated Galectin-9 Suppresses Th1 Effector Function and Induces Apoptosis of Activated CD4+ T Cells in Osteoarthritis" Jun. 2017, Inflammation 40(3):1062-1071 (abstract).
Zapata et al. "Engineering linear F(ab′)2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity" Oct. 1, 1995, Protein Eng. 8(10):1057-1062.
Angal et al. "A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (lgG4) antibody" Jan. 1993, Mol. Immunol. 30(1):105-108.
Clackson et al. "Making antibody fragments using phage display libraries" Aug. 15, 1991, Nature 352(6336):624-628.
Gennaro, "Remington: The Science and Practice of Pharmacy" 20th ed., 2003 (Cover and TOC).
Green et al. "Molecular Cloning: A Laboratory Manual" 4th Ed, 2012, Cold Spring Harbor Laboratory Press, Woodbury, NY (2,028 pages).
Haeckel et al. "XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic2" Jun. 13, 2016, PLoS One 11(6):e0157193.
Harlow and Lane, Antibodies, A Laboratory Manual, 1st Ed., 1988, Cold Springs Harbor Press—726 Pages—Background only—Abstract only (ISBN: 0879693142).
Hoogenboom et al. "By-passing Immunization: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro" 1992, J. Mol. Biol. 227(2):381-388.
International Search Report and Written Opinion for PCT/CN2021/070473 mailed Jun. 14, 2021.
International Search Report and Written Opinion for PCT/CN2021/103889 mailed Mar. 31, 2022.
International Search Report and Written Opinion for PCT/US2023/070259 dated Dec. 13, 2023 (21 pages).
Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., 2000, Pharmaceutical Press (12 pages).
Lhuillier C, et al. Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9. PLoS One. Sep. 11, 2018;13(9):e0202512. doi: 10.1371/journal.pone.0202512. PMID: 30204750; PMCID: PMC6133441. (Year: 2018). *
Marks et al. "By-passing immunization. Human antibodies from V-gene libraries displayed on phage" Dec. 1991, J. Mol. Biol. 222(3):581-597.
Morel et al. "Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations" Jan. 1988, Molec. Immunol. 25(1):7-15.
Morimoto et al. "Single-step purification of F(ab′)2 fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW" Mar. 1992, J. Biochem. Biophys. Methods 24(1-2):107-117.
Morrison et al. "Transfectomas provide novel chimeric antibodies" Sep. 20, 1985, Science 229(4719):1202-1207.
Nasonov, "Immune Checkpoint Inhibition and Autoimmunity: Rhemuatological Problems", Rheumatology Science and Practice, 2018, 56(1):5-9 (in Russian, with English Abstract).
Oi et al. "Chimeric Antibodies" 1986, BioTechniques 4:214-221.
Pluckthun, "Antibodies from Escherichia coli."1994, The Pharmacology of Monoclonal Antibodies 113:269-315, Rosenberg and Moore eds., Springer-Verlag, NY—Background only—Abstract only.
Raybould et al. "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" 2019 PNAS USA 116(10):4025-4030.
Safdari et al. "Antibody humanization methods—a review and update" 2013, Biotech. And Genetic Engineering Reviews 29(2):175-186.
Sitaraman et al. "High-throughput protein expression using cell-free system" 2009, Methods Mol. Biol. 498:229-244.
Strickley et al "A review of formulatons of commercially available antibodies" Jul. 2021, J. Pharm. Sci. 110(7):2590-2608.e56.
Tyner et al. "Functional Genomic Landscape of Acute Myeloid Leukaemia" Oct. 2018, Nature 562(7728):526-531.
U.S. Appl. No. 18/995,102, filed Jul. 14, 2023, Olsen, David. *
Valldorf et al. "Antiobody Display Technologies: selecting the cream of the crop" 2022, Biol. Chem. 403(506):4550477.
Warszawski et al. "Optimizing Antibody Affinity and Stability by the Automated Design of the Variable Light-Heavy Chain Interfaces" Aug. 23, 2019, PloS Comput. Biol. 16(10):e100207 (http://doi.org/10.1371/journal.pcbi.1007207).
Weber et al. "From rabbit antibody repertoires to rabbit monoclonal antibodies" Mar. 24, 2017, Exp. Mol. Med. 49: e305.
Wu et al. "Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells" 2014, Immunity 41(2):270-282.
Yang et al. "Elevated Galectin-9 Suppresses Th1 Effector Function and Induces Apoptosis of Activated CD4+ T Cells in Osteoarthritis" Jun. 2017, Inflammation 40(3):1062-1071 (abstract).
Zapata et al. "Engineering linear F(ab′)2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity" Oct. 1, 1995, Protein Eng. 8(10):1057-1062.

Also Published As

Publication number Publication date
BR112022013494A2 (pt) 2022-09-13
KR20220123105A (ko) 2022-09-05
JP7719799B2 (ja) 2025-08-06
CN120647763A (zh) 2025-09-16
CN115210261B (zh) 2025-07-18
CN115210261A (zh) 2022-10-18
CA3163988A1 (en) 2021-07-15
MX2022008421A (es) 2022-09-23
WO2021139682A1 (en) 2021-07-15
IL294466A (en) 2022-09-01
AU2021205143A1 (en) 2022-07-28
US20230054718A1 (en) 2023-02-23
EP4087873A1 (en) 2022-11-16
JP2023510429A (ja) 2023-03-13

Legal Events

Date Code Title Description
AS Assignment

Owner name: HIFIBIO (HK) LIMITED, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARGALL DUCOS, GERMAIN;PACHERIE, RACHEL;BELTRAMINELLI, NICOLA ARTURO ALDO;AND OTHERS;SIGNING DATES FROM 20220624 TO 20220628;REEL/FRAME:060358/0279

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: HIFIBIO, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HIFIBIO (HK) LIMITED;REEL/FRAME:066331/0216

Effective date: 20231220

AS Assignment

Owner name: HIFIBIO, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HIFIBIO (HK) LIMITED;REEL/FRAME:066347/0278

Effective date: 20231220

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE